PIII — P3 Health Partners Inc.

P3 Health Partners Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted EBITDA: $26 million, exceeding internal expectations and a significant improvement from a loss of $22 million in Q1 2025.
• Revenue: $386 million, up from $373 million year-over-year, despite a decline in membership.
• At-Risk Membership: Approximately 106,000, down from 118,000 in Q1 2025, reflecting strategic exits from less profitable arrangements.
• Medical Claims Expense: $306 million, including $17 million in favorable prior year development and payer settlements.
• Medical Margin: $74 million, with a medical loss ratio of 85.2%, adjusted for prior year items.
• Cash Position: Ended the quarter with $25 million in cash and equivalents.

2. Strategic Updates and Business Highlights

• Operational Improvements: Significant restructuring in payer contracts and operational redesign have led to improved financial performance and operational execution.
• Payer Contract Enhancements: Improved risk funding and cost accountability structures have resulted in a 15% year-over-year increase in Medicare Advantage funding rates and expanded delegated functions to 63% of membership.
• Clinical Performance: The company reported flat medical cost trends, significantly lower than industry averages, attributed to enhanced clinical programs and utilization management.
• Partnership Expansion: A new partnership in Nebraska added 28,600 lives under management, reflecting a disciplined growth strategy.

3. Forward Guidance and Outlook

• Revised Full-Year 2026 Adjusted EBITDA Outlook: Increased to a range of $20 million to $60 million, with a midpoint of $40 million, based on strong Q1 performance and ongoing operational improvements.
• Long-Term Focus: The company aims to continue enhancing medical margins, improving contract economics, and scaling operations in favorable markets.

4. Bad News, Challenges, or Points of Concern

• Membership Decline: The reduction in at-risk membership raises concerns about growth potential, although it is part of a strategic focus on quality over quantity.
• Dependency on Payer Relationships: The success of the business model heavily relies on maintaining and expanding relationships with payers, which could be a risk if market dynamics change.
• Operational Execution Risks: While improvements have been noted, ongoing execution is critical, and any setbacks could impact financial performance.

5. Notable Q&A Insights

• Utilization Trends: Management noted a proactive reduction in Part B costs, with expectations for Part D medical loss ratios to trend higher as members reach out-of-pocket maximums.
• Payer Partner Expansion: The improved financial position and positive momentum are expected to enhance attractiveness to potential payer partners, supporting growth strategies.
• Pathway to Increased Delegation: Management outlined a structured approach to increase delegation beyond the current 63%, emphasizing the need for audits and testing before full delegation can be achieved.

Overall, P3 Health Partners demonstrated a strong start to 2026, with significant improvements in financial performance and operational execution, while also navigating challenges related to membership and reliance on payer relationships.